EuroPCR 2024: Late-Breaking Science Video Collection
Published: 20 May 2024
-
Views:
1043
-
Likes:
7
-
Views:
1043
-
Likes:
7
-
26m 3sPart 2 | Session 1 View from the Thoraxcenter: What's Hot at EuroPCR 24? -
18m 29sPart 2 | Session 2 View from the Thoraxcenter: EuroPCR 24 Wrap Up - Part 1
-
4m 13sPart 3 | Session 1 5 Trials That Will Change My Practice With Dr Mirvat Alasnag -
6m 27sPart 3 | Session 2 4 Trials That Will Change My Practice with Dr Bernardo Cortese
-
4m 31sPart 1 | Session 1 Self-Expandable Vs Balloon-Expandable Valves & General Vs Local Anesthesia in TAVI: SOLVE-TAVI Hans-Josef Feistritzer
-
3m 44sPart 1 | Session 2 Influence of Pathophysiological Patterns of CAD on PCI Carlos Collet
-
5m 19sPart 1 | Session 3 Ancillary SMART Trial Analyses Roxana Mehran
-
3m 59sPart 1 | Session 4 Impact of Diabetes Severity After Abluminus DES+ Stent: ABILITY Roxana Mehran
-
4m 6sPart 1 | Session 5 TAVR Vs SAVR in Younger Low-Risk Patients with Severe Aortic Valve Stenosis: NOTION-2 Ole De Backer
Overview
Our regular review series View From the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) dives deep into the late-breaking trials of EuroPCR 2023, spotlighting the impactful data.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
Hear commentary on the practice-changing trials of EuroPCR 2024 from selected faculty in our Highlights Reviews.
More from this programme
Part 1
Expert Interviews
Part 2
View from the Thoraxcenter
Part 3
Highlights Reviews
About the episode
EuroPCR 2024 — Investigator, Dr Ling Tao joins us to discuss the findings from the CAGEFREE II trial.
Compared to drug-eluting stents, drug-coated balloons are associated with faster vessel healing and reduced thrombotic burden, therefore patients treated with DCBs require a less intensive antiplatelet therapy. CAGEFREE II investigated the effectiveness and safety of a tailored one-month DAPT followed by 5-month Ticagrelor monotherapy in patients with acute coronary syndromes with DCB.
Questions:
- What is the existing evidence supporting low-intensity antiplatelet regimen?
- What question does this trial aim to address?
- What was the design, eligibility criteria, and outcome measures?
- What were the baseline characteristics of the randomized patients?
- What are the key findings?
- What are the implications for practice?
- What further research is required?
Recorded on-site at EuroPCR, 2024.
Comments